ARTICLE
20 November 2024

Medtech M&A And Venture Investments Show Renewed Strength

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
The medtech sector is showing promising signs of recovery in both mergers and acquisitions (M&A) activity and venture capital (VC) investments.
United States Corporate/Commercial Law

The medtech sector is showing promising signs of recovery in both mergers and acquisitions (M&A) activity and venture capital (VC) investments.

Medtech M&A Transactions Pick Up

M&A activity in 2024 has been robust, with 195 deals announced through the third quarter, already exceeding the 128 transactions for the entirety of 2023. Deal value totaled about $47 billion through the third quarter, on pace to surpass 2023's full-year total of $50.1 billion.

The Federal Reserve's expected interest rate cuts and anticipated deregulation from the incoming presidential administration could further boost M&A activity in 2025.

1547496a.jpg

Medtech VC Investment Set to Strengthen

VC investments into medtech companies are projected to reach $21.5 billion by year-end, a 27% increase from the $16.9 billion recorded in 2023. This strong growth would follow a two-year slowdown in medical-device investment amid rising interest rates, economic uncertainty, and a more cautious funding environment following the pandemic-era boom.

VC funding into medtech will likely gain momentum in 2025 as interest rates decline and further advancements in AI-driven technologies continue to attract investor interest.

1547496b.jpg

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More